Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studiesYoshiaki Nakamura, Takayuki Yoshino, Wataru Okamoto et al.|Nature Medicine|2020Cited by 366
Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal CancerJun Watanabe, Takayuki Yoshino, Kei Muro et al.|JAMA|2023Cited by 255
Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancerKohei Shitara, Takayuki Yoshino, Kei Muro et al.|Nature Medicine|2024Cited by 108
Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial.Takayuki Yoshino, Kei Muro, Jun Watanabe et al.|Journal of Clinical Oncology|2022Cited by 69
Association of variations in HLA class II and other loci with susceptibility to EGFR-mutated lung adenocarcinomaKouya Shiraishi, Takashi Kohno, Yukinori Okada et al.|Nature Communications|2016Cited by 58